Health
globalreutersNovember 26, 20241 Mins read
Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition
globalreutersNovember 26, 20241 Mins read 
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.
The post Roche Expands Its Scope in Allogeneic Cell Therapy With $1B Poseida Therapeutics Acquisition appeared first on MedCity News.
Related Articles
What to Know Ahead of the Supreme Court Case on Youth Access to Gender Affirming Care
This brief provides background on gender affirming care and state bans, explains...
Stick to the Science
By KIM BELLARD A year ago I wrote about disturbing news from...
FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug
BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer...
What is HEMA?
The Pink Sheet reports on a new international health technology assessment (HTA)...
Leave a comment